NEUMORA THERAPEUTICS, INC.

Highlights Neumora Therapeutics, Inc.

Equities

NMRA

US6409791000

Market Closed - Nasdaq Other stock markets 01:30:00 01/06/2024 am IST			5-day change	1st Jan Change
9.9 ^USD	+2.17%		+7.96%	-41.94%

14/05	Transcript : Neumora Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:00 AM
14/05	Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression	14/05	CI
Neumora Therapeutics Shares Fall as Q1 Loss Narrows	07/05	MT
Neumora Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
Sector Update: Health Care Stocks Advance Premarket Monday	15/04	MT
Sector Update: Health Care	15/04	MT
Upcoming Earnings Buoy Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday	15/04	MT
Neumora Therapeutics' Phase 1 Trial of Potential Brain Disease Drug on Hold After Convulsions in Rabbits	15/04	MT
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study	15/04	CI
Neumora Therapeutics Q4 Loss Narrows	07/03	MT
Neumora Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03	CI
Neumora Therapeutics, Inc. Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study	27/11	CI
Neumora Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	01/11	CI
Marketing firm Klaviyo lifts IPO price range, targets $9 bln valuation	18/23/18	RE
Neumora Therapeutics, Inc. has completed an IPO in the amount of $250.07 million.	14/23/14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+201.5% on SUPER MICRO COMPUTER since our purchase on February 17, 2023

Replicate our performance

fermer